Jiangsu Baju Pharmaceutical Co., Ltd. is an enterprise established by Zhejiang Chetou Pharmaceutical Co., Ltd. in Binhai in December 2003. It primarily produces antiviral, anti-inflammatory and analgesic, cardiovascular, antitumor, and other series of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It is a national high-tech enterprise and a provincial-level pharmaceutical engineering technology research center. The company has two plant areas, north and south, with a total of approximately 780 employees, a total land area of about 400 mu, total assets of about 600 million yuan, and a registered capital of 150 million yuan. In February 2015, the company merged with its parent company, Zhejiang Chetou Pharmaceutical Co., Ltd., and was listed on the New Third Board.

The company's products have established leading technological advantages and production scale domestically and have gained certain recognition in European and American markets. The products are mainly sold to internationally renowned pharmaceutical companies such as Bayer in Germany, DSM in the Netherlands, TEVA in Israel, and Perrigo in the United States, with long-term cooperative relationships established. The parent company has repeatedly passed GMP inspections and certifications from regulatory authorities including the China National Medical Products Administration (NMPA), the U.S. FDA, the European Union's EDQM, Brazil's ANVISA, South Korea's KFDA, and Mexico's Cofepris. Its quality management system continues to cover the company and is continuously improved.

The company continues to increase investment in safety and environmental protection. In terms of safety, ongoing automation upgrades include DCS and ESD control systems, centralized hydrogen and nitrogen supply systems, automated tank farm control systems, automated control systems for some workshops, and automation upgrades for fire protection systems. In environmental protection, two sets of RTO furnaces for waste gas incineration, two sets of carbon fiber adsorption devices for waste gas, two sets of electrostatic adsorption devices for dust, one set of MVR evaporation system for high-salt wastewater, and one set of solid waste incinerator have been installed. Additionally, upgrades have been made to the wastewater separation system for rainwater and sewage, as well as the clean and dirty water separation system.

The company adheres to a market-oriented approach, vigorously developing lightly polluting, high-tech pharmaceutical intermediates. As a producer of pharmaceutical intermediates, technological innovation is essential for survival. Since its establishment, the company has prioritized technological improvements of existing products, research and development of new products, and technical cooperation as key measures for enterprise development. The company has nearly 100 professional R&D and quality management personnel across its north and south areas, including over 15 master's degree holders. Annual R&D investment accounts for more than 5% of the company's sales revenue. The company has established cooperative relationships with Huaihai Institute of Technology, Sichuan University, Wuhan Institute of Technology, and East China University of Science and Technology. After more than a decade of effort, it has successively been recognized as a municipal and provincial high-tech enterprise.

The company will continue to increase investment in automated equipment and facilities, technological innovation, talent team building, and corporate culture development. All employees will provide more professional and standardized technologies, products, and services for the health of all humanity.